Results of the multivariable analysis for CEBPAbi vs CEBPAsmbZIP vs CEBPAsmTAD
| . | OS (HR) . | P . | 95% CI . | EFS (HR) . | P . | 95% CI . | CR1 (OR) . | P . | 95% CI . |
|---|---|---|---|---|---|---|---|---|---|
| Intermediate karyotype | 1 | 1 | 1 | ||||||
| Favorable karyotype | 0.426 | <.001 | (0.35-0.51) | 0.400 | <.001 | (0.34-0.47) | 3.076 | <.001 | (2.08-4.56) |
| Adverse karyotype* | 1.853 | <.001 | (1.68-2.04) | 1.625 | <.001 | (1.49-1.78) | 0.476 | <.001 | (0.40-0.58) |
| Age | 1.032 | <.001 | (1.03-1.04) | 1.023 | <.001 | (1.02-1.03) | 0.948 | <.001 | (0.94-0.95) |
| Log10 WBC | 1.158 | <.001 | (1.08-1.24) | 1.231 | <.001 | (1.16-1.31) | 0.751 | <.001 | (0.66-0.86) |
| De novo AML | 1 | 1 | 1 | ||||||
| sAML | 1.088 | .127 | (0.98-1.21) | 1.069 | .189 | (0.97-1.18) | 0.735 | .003 | (0.60-0.90) |
| tAML | 1.380 | <.001 | (1.19-1.60) | 1.098 | .186 | (0.96-1.26) | 0.697 | .009 | (0.53-0.91) |
| No FLT3-ITDmut | 1 | 1 | 1 | ||||||
| FLT3-ITDmut | 1.204 | <.001 | (1.09-1.33) | 1.238 | <.001 | (1.13-1.35) | 1.018 | .866 | (0.83-1.25) |
| No NPM1mut | 1 | 1 | 1 | ||||||
| NPM1mut | 0.625 | <.001 | (0.57-0.69) | 0.531 | <.001 | (0.49-0.58) | 2.151 | <.001 | (1.77-2.62) |
| CEBPAwt | 1 | 1 | 1 | ||||||
| CEBPAbi | 0.507 | <.001 | (0.39-0.67) | 0.530 | <.001 | (0.42-0.67) | 6.367 | <.001 | (2.75-14.77) |
| CEBPAsmbZIP | 0.620 | .019 | (0.42-0.92) | 0.537 | .001 | (0.37-0.77) | 1.876 | .139 | (0.81-4.32) |
| CEBPAsmTAD | 1.024 | .878 | (0.75-1.39) | 0.981 | .891 | (0.74-1.31) | 0.825 | .515 | (0.46-1.48) |
| No allo-HSCT in CR1 | 1 | 1 | 1 | ||||||
| Allo-HSCT in CR1 | 0.776 | <.001 | (0.69-0.87) | 0.632 | <.001 | (0.56-0.71) | — | — | — |
| . | OS (HR) . | P . | 95% CI . | EFS (HR) . | P . | 95% CI . | CR1 (OR) . | P . | 95% CI . |
|---|---|---|---|---|---|---|---|---|---|
| Intermediate karyotype | 1 | 1 | 1 | ||||||
| Favorable karyotype | 0.426 | <.001 | (0.35-0.51) | 0.400 | <.001 | (0.34-0.47) | 3.076 | <.001 | (2.08-4.56) |
| Adverse karyotype* | 1.853 | <.001 | (1.68-2.04) | 1.625 | <.001 | (1.49-1.78) | 0.476 | <.001 | (0.40-0.58) |
| Age | 1.032 | <.001 | (1.03-1.04) | 1.023 | <.001 | (1.02-1.03) | 0.948 | <.001 | (0.94-0.95) |
| Log10 WBC | 1.158 | <.001 | (1.08-1.24) | 1.231 | <.001 | (1.16-1.31) | 0.751 | <.001 | (0.66-0.86) |
| De novo AML | 1 | 1 | 1 | ||||||
| sAML | 1.088 | .127 | (0.98-1.21) | 1.069 | .189 | (0.97-1.18) | 0.735 | .003 | (0.60-0.90) |
| tAML | 1.380 | <.001 | (1.19-1.60) | 1.098 | .186 | (0.96-1.26) | 0.697 | .009 | (0.53-0.91) |
| No FLT3-ITDmut | 1 | 1 | 1 | ||||||
| FLT3-ITDmut | 1.204 | <.001 | (1.09-1.33) | 1.238 | <.001 | (1.13-1.35) | 1.018 | .866 | (0.83-1.25) |
| No NPM1mut | 1 | 1 | 1 | ||||||
| NPM1mut | 0.625 | <.001 | (0.57-0.69) | 0.531 | <.001 | (0.49-0.58) | 2.151 | <.001 | (1.77-2.62) |
| CEBPAwt | 1 | 1 | 1 | ||||||
| CEBPAbi | 0.507 | <.001 | (0.39-0.67) | 0.530 | <.001 | (0.42-0.67) | 6.367 | <.001 | (2.75-14.77) |
| CEBPAsmbZIP | 0.620 | .019 | (0.42-0.92) | 0.537 | .001 | (0.37-0.77) | 1.876 | .139 | (0.81-4.32) |
| CEBPAsmTAD | 1.024 | .878 | (0.75-1.39) | 0.981 | .891 | (0.74-1.31) | 0.825 | .515 | (0.46-1.48) |
| No allo-HSCT in CR1 | 1 | 1 | 1 | ||||||
| Allo-HSCT in CR1 | 0.776 | <.001 | (0.69-0.87) | 0.632 | <.001 | (0.56-0.71) | — | — | — |
The multivariable analysis performed includes the different study regimens as strata.
Adverse karyotype according to ELN 2017.